Studies blood markers that may predict early atrial fibrillation in device patients

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have had a dual chamber pacemaker or defibrillator implanted in the last 10 years and have no documented atrial fibrillation.

Age

18 years or older

Sex

All sexes can join

Disease stage

No clinical atrial fibrillation documented by surface ECG (12 lead ECG, Telemetry, Holter)

Earlier treatment

Dual chamber permanent pacemaker or defibrillator implanted within the previous 10 years

Main reasons for not taking part

• Clinical atrial fibrillation documented by surface ECG
• Life expectancy less than 2 years due to concomitant disease
• Pregnant or breast-feeding
• Congenital heart disease
• Inherited arrhythmia syndrome, i.e. Brugada, long QT interval

The registry criteria, word for word

What the trial wants to find out

Atrial fibrillation (AF) often starts with short episodes of rapid irregular heartbeats that are only detected by implanted pacemakers or defibrillators. Usually people don't know that they have these episodes. Over time, these episodes can happen more often and last for longer periods. In some people, the heart eventually remains permanently in a fast irregular rhythm, known as atrial fibrillation. This condition can lead to strokes and blood clots. If physicians could detect atrial fibrillation at a very early stage they could treat people early and possibly prevent the condition from becoming permanent. People with implanted devices allow a unique opportunity to constantly monitor the heart rhythm so investigators can detect any irregularities immediately.